EXACT Sciences Co. (NASDAQ:EXAS) SVP D Scott Coward sold 4,420 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $42.34, for a total value of $187,142.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
D Scott Coward also recently made the following trade(s):
- On Wednesday, January 3rd, D Scott Coward sold 1,665 shares of EXACT Sciences stock. The stock was sold at an average price of $52.54, for a total value of $87,479.10.
Shares of EXACT Sciences Co. (EXAS) traded up $1.81 during trading hours on Tuesday, hitting $44.37. The company had a trading volume of 4,378,424 shares, compared to its average volume of 3,460,000. The company has a current ratio of 7.15, a quick ratio of 6.77 and a debt-to-equity ratio of 0.01. EXACT Sciences Co. has a twelve month low of $19.91 and a twelve month high of $63.60. The stock has a market capitalization of $5,310.00, a price-to-earnings ratio of -21.75 and a beta of 0.58.
Large investors have recently made changes to their positions in the stock. Chicago Equity Partners LLC purchased a new stake in shares of EXACT Sciences during the third quarter worth $2,312,000. Columbus Circle Investors raised its holdings in shares of EXACT Sciences by 5.5% during the third quarter. Columbus Circle Investors now owns 133,398 shares of the medical research company’s stock worth $6,286,000 after acquiring an additional 6,965 shares in the last quarter. Hodges Capital Management Inc. purchased a new stake in shares of EXACT Sciences during the third quarter worth $18,771,000. Emerald Advisers Inc. PA purchased a new stake in shares of EXACT Sciences during the fourth quarter worth $21,813,000. Finally, Advisors Management Group Inc. ADV purchased a new stake in shares of EXACT Sciences during the third quarter worth $317,000. Institutional investors and hedge funds own 84.88% of the company’s stock.
Several analysts have recently commented on the company. Zacks Investment Research raised EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a research report on Tuesday, January 16th. BidaskClub raised EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. William Blair reaffirmed a “buy” rating on shares of EXACT Sciences in a research report on Wednesday, January 10th. Robert W. Baird raised EXACT Sciences from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $42.56 to $56.00 in a research report on Tuesday. Finally, Goldman Sachs Group assumed coverage on EXACT Sciences in a research report on Monday, January 29th. They issued a “neutral” rating and a $51.00 target price for the company. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $52.84.
ILLEGAL ACTIVITY WARNING: This story was first posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3226631/insider-selling-exact-sciences-co-exas-svp-sells-4420-shares-of-stock.html.
EXACT Sciences Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.